FY2022

CERTIFICATE OF REGISTRATION

This certifies that:

Analyst Research Laboratories Ltd
2 Ilan Ramon
Ness Ziona 7403635
Israel

is registered with the U.S. Food and Drug Administration for the statutory filing period applicable to U.S. FY 2022 pursuant to part 207 of Title 21, U.S. Code of Federal Regulations.

DUNS Number:	**53-228-5988**
Labeler Code:	**01500**
FEI:	**3004153798**
U.S. Agent/Registrant Contact:	**Registrar Corp** 144 Research Drive, Hampton, Virginia, 23666, USA Telephone: +1-757-224-0177 • Fax: +1-757-224-0179

Filing was performed during the October 1 - December 31, 2021 statutory period, and renewal is not required until the next statutory period of October 1 - December 31, 2022. Registrar Corp will confirm that such registration remains effective upon request and presentation of this certificate, until the end of the year stated above, unless terminated after issuance of this certificate. Registrar Corp makes no other representations or warranties, nor does this certificate make any representations or warranties to any person or entity other than the named certificate holder, for whose sole benefit it is issued. Registrar Corp assumes no liability to any person or entity in connection with the foregoing. Registration of a drug establishment or drug wholesaler, or assignment of a registration number, or assignment of a NDC number does not in any way denote approval of the firm or its products by the U.S. Food and Drug Administration. Any representation that creates an impression of official approval because of registration or possession of registration number or NDC number is misleading and constitutes misbranding. The U.S. Food and Drug Administration does not issue a certificate of registration, nor does the U.S. Food and Drug Administration recognize a certificate of registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.

Registrar Corp
144 Research Drive, Hampton, Virginia, 23666, USA
Telephone: +1-757-224-0177 • Fax: +1-757-224-0179
info@registrarcorp.com • www.registrarcorp.com

David Lennarz
Executive Director
Registrar Corp
Dated: October 25, 2021

Registrar Corp
144 Research Drive, Hampton, Virginia 23666 USA
Phone: +1-757-224-0177 * Fax: +1-757-224-0179 * Email: info@registrarcorp.com * Website: www.registrarcorp.com

October 25, 2021

Analyst Research Laboratories Ltd
2 Ilan Ramon
Ness Ziona 7403635
Israel

Re: U.S. FDA Drug Establishment Registration Renewal Certificate

Good Day,

We enclose the Certificate of Registration issued by Registrar Corp verifying that your firm's drug establishment registration has been electronically updated with FDA for Fiscal Year 2022 (FY2022).

We advise that FDA has changed its requirement for annual registration. The Food and Drug Administration Safety and Innovation Act of 2012 ("FDASIA"), which was signed into law on July 9, 2012, requires that all registrants renew their Drug Establishment Registrations between October 1 and December 31 of each year. To comply with this statutory requirement, we submitted your registration during this period. Your next renewal period will be October 1 to December 31, 2022. You will be sent documents to verify the accuracy of your information again at that time.

Registrar Corp will send you color copies of your certificates by email. You may wish to use the electronic version to forward copies of your company's certificates to your customers and suppliers so they are aware that your company has complied with FDA's registration requirements. Please note, however, that pursuant to 21 CFR § 207.77(a), "Registration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or other drugs of the establishment, nor does it mean that a product may be legally marketed. Any representation that creates an impression of official approval or that a drug is approved or is legally marketable because of registration or listing is misleading and constitutes misbranding." This means that the enclosed certificate does not denote endorsement or approval by the U.S. FDA, and it should not be used to suggest such an inference.

As your U.S. Agent and Registrant Contact, Registrar Corp will continue to serve as a communications link between the U.S. FDA and your company for your electronic submissions. If we receive any correspondence from the U.S. FDA for your company regarding your electronic submissions, we will notify you by fax, email, or phone. In addition, we will be pleased to complete electronic submissions for any drug products not already listed with the U.S. FDA which you may introduce to market.

Please contact us if you have any questions or need additional help with FDA compliance.

Sincerely,

David Lennarz
President